Table 2. Practitioner participation, Influenza-like illness (ILI) patients recruited by case control status, vaccination status, and study site, I-MOVE multi-centre case control study, influenza season 2010-11.
Study site | Number of practitioners in the National sentinel system | Number of practitioners accepting to participate in the study | Number of practitioners recruiting at least one ILI * | Number of ILI patients* recruited by practitioners | Inclusion period for the study† | Number of ILI patients included in the study positive for influenza ‡ | Number of ILI patients included in the study negative for influenza ‡ | ||
Total | Vaccinated | Total | Vaccinated | ||||||
France | 571 | 425 | 317 | 1186 | wk 51, 2010 –wk 11, 2011 | 597 | 15 | 589 | 39 |
Hungary | 1400 | 98 | 78 | 727 | wk 50, 2010 –wk 13, 2011 | 119 | 4 | 608 | 52 |
Ireland | 135 | 48 | 17 | 190 | wk 48, 2010 –wk 9, 2011 | 106 | 0 | 84 | 6 |
Italy | 1009+ | 38 | 27 | 415 | wk 46, 2010 –wk 13, 2011 | 116 | 17 | 299 | 64 |
Poland | 971 | 33 | 29 | 180 | wk 48, 2010 –wk 14, 2011 | 98 | 6 | 81 | 10 |
Portugal | 144 | 58 | 34 | 253 | wk 45, 2010 –wk 11, 2011 | 144 | 6 | 109 | 19 |
Romania | 270 | 89 | 66 | 255 | wk 52, 2010 –wk 15, 2011 | 154 | 7 | 101 | 13 |
Spain | 848 | 246 | 197 | 1205 | wk 49, 2010 –wk 12, 2011 | 685 | 26 | 520 | 53 |
Total | 5348 | 1035 | 765 | 4410 | 2019 | 81 | 2391 | 256 |
*ILI patients meeting the EU case definition, swabbed < 8 days after onset of symptoms within the study period.
For each study site, from 15 days after the start of the vaccination campaign up to the week that preceded two consecutive weeks in which none of the ILI patients recruited tested positive for influenza. Week number as defined by the International Standards Organization to ensure consistency across study sites (ISO weeks used).
ILI patients in the study after applying exclusion criteria (contraindications for vaccine, antiviral use before swabbing, missing lab results) and excluding those not adhering to the EU ILI case definition, having a delay between symptom onset and swabbing of less than 8 days and presenting outside the study period.
Mean number of participating GPs.